<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04970602</url>
  </required_header>
  <id_info>
    <org_study_id>20210621</org_study_id>
    <nct_id>NCT04970602</nct_id>
  </id_info>
  <brief_title>The Effect of Early Use of Methylene Blue on Hemodynamics in Septic Shock</brief_title>
  <official_title>The Effect of Early Use of Methylene Blue on Hemodynamics in Septic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xiangya Hospital of Central South University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will include patients requiring high dose of norepinephrine (NA) to maintain blood&#xD;
      pressure after fluid resuscitation. The patients will be randomized into two groups, the&#xD;
      study protocol is early combined application of methylene blue. The primary outcome is&#xD;
      Sequential Organ Failure Assessment (SOFA) score 72 hours after admission. Second outcome&#xD;
      includes duration of shock, length of intensive care unit (ICU) hospitalization and so on. To&#xD;
      explore the underlying mechanism, the changes of sublingual microcirculation before and after&#xD;
      vasopressor combination will be collected, also is the global longitudinal strain of left&#xD;
      ventricle.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Decreased vascular tone is one of the main mechanisms leading to septic shock.&#xD;
      The guidelines recommend NA as the first-line vasopressor. The benefits of early combination&#xD;
      with other vasopressors are not yet known.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
        1. Patients: Septic shock patients in need of high dose of NA (≥0.5ug/kg.min maintaining&#xD;
           more than 2 hours) to maintain blood pressure after fluid resuscitation.&#xD;
&#xD;
        2. Intervention: The patients will be randomized into two groups. The study group will&#xD;
           receive 2mg/kg methylene blue infusion with 15 minutes, 2 hours laters followed by&#xD;
           0.5mg/kg/h for 4 hours. The control group received conventional treatments, the&#xD;
           attending physicians decide the protocol of vasopressors. The data including patients'&#xD;
           characters, duration of shock and hospitalization, duration of mechanical ventilation,&#xD;
           cumulative dose of vasopressors will be collected. Before and 6h after meeting the&#xD;
           inclusion standard, sublingual microcirculation and automated function imaging of&#xD;
           myocardium will be performed.&#xD;
&#xD;
        3. Outcome: The primary outcome is SOFA score 72 hours after admission. Second outcome&#xD;
           includes duration of shock, length of ICU hospitalization and so on. the changes of&#xD;
           sublingual microcirculation will be collected, also is the global longitudinal strain of&#xD;
           left ventricle.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 20, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SOFA score</measure>
    <time_frame>72 hours</time_frame>
    <description>72 hours after inclusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>duration of shock</measure>
    <time_frame>2 hours</time_frame>
    <description>the duration between diagnosis and relief of septic shock, the latter is defined by stable blood pressure without any vasopressor for 2 hours</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">106</enrollment>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>MB group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will be given 2mg/kg methylene blue infusion within 20 minutes, 2 hours later followed by 0.5mg/kg/h for 4 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This group will be given conventional vasopressors, except methylene blue, based on the attending doctor's decision.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylene Blue</intervention_name>
    <description>Once the patient meets inclusion criterial, the interventional group will receive 2mg/kg methylene blue infusion within 20min, followed by 0.5mg/kg/h for 4 hours.</description>
    <arm_group_label>MB group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Septic shock, receive 0.5 ug/kg/min NA to maintain blood pressure for more than 2&#xD;
             hours after fluid resuscitation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Without internal jugular vein or subclavian vein catheterization&#xD;
&#xD;
          -  Child-Pugh grade C with liver cirrhosis&#xD;
&#xD;
          -  Severe chronic obstructive pulmonary disease (severe acidosis caused by type II&#xD;
             respiratory failure, PaCO2 ≥60mmHg and PH&lt;7.2 )&#xD;
&#xD;
          -  End-stage of malignant tumors&#xD;
&#xD;
          -  Glucose-6-phosphate dehydrogenase (G6PD enzyme) deficiency&#xD;
&#xD;
          -  Positive end-respiratory pressure (PEEP) &gt;10mmHg, the oxygenation index &lt;150mmHg under&#xD;
             mechanical ventilation&#xD;
&#xD;
          -  Definitive pulmonary hypertension or chronic pulmonary heart disease.&#xD;
&#xD;
          -  Oral use of 5-hydroxytryptamine in recent 3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiangya Hospital, Central South University</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Critical Care Medicine, Xiangya Hospital, Central South University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Xiangya Hospital, Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 29, 2021</study_first_submitted>
  <study_first_submitted_qc>July 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2021</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>septic shock</keyword>
  <keyword>methylene blue</keyword>
  <keyword>vasopressor</keyword>
  <keyword>refractory shock</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylene Blue</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The study protocol, objective data could be shared when required.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Within 1 year after completion of the study.</ipd_time_frame>
    <ipd_access_criteria>Just for academic requirement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

